The Role of Acrolein in Neurodegenerative Diseases and Its Protective Strategy

Overview

Journal Foods

Specialty Biotechnology

Date 2023 Jul 11

PMID 37430952

Authors

Xinxin Chang

Yudan Wang

Bing Zheng

Yi Chen

Jianhua Xie

Yiming Song

Xiaomeng Ding

Xiaoyi Hu

Xiaobo Hu

Qiang Yu

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases are characterized by a massive loss of specific neurons, which can be fatal. Acrolein, an omnipresent environmental pollutant, is classified as a priority control contaminant by the EPA. Evidence suggests that acrolein is a highly active unsaturated aldehyde related to many nervous system diseases. Therefore, numerous studies have been conducted to identify the function of acrolein in neurodegenerative diseases, such as ischemic stroke, AD, PD, and MS, and its exact regulatory mechanism. Acrolein is involved in neurodegenerative diseases mainly by elevating oxidative stress, polyamine metabolism, neuronal damage, and plasma ACR-PC levels, and decreasing urinary 3-HPMA and plasma GSH levels. At present, the protective mechanism of acrolein mainly focused on the use of antioxidant compounds. This review aimed to clarify the role of acrolein in the pathogenesis of four neurodegenerative diseases (ischemic stroke, AD, PD and MS), as well as protection strategies, and to propose future trends in the inhibition of acrolein toxicity through optimization of food thermal processing and exploration of natural products.

Citing Articles

A comprehensive bibliometric analysis of global research on the role of acrolein in Alzheimer's disease pathogenesis: involvement of amyloid-beta.

Jallow A, Nguyen D, Sanotra M, Hsu C, Lin Y, Lin Y Front Aging Neurosci. 2024; 16:1378260.

PMID: 38784445 PMC: 11111988. DOI: 10.3389/fnagi.2024.1378260.

Urinary acrolein protein conjugates-to-creatinine ratio is positively associated with diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.

Wu T, Su G, Liu T, Wang H, Hwu C Endocr Connect. 2023; 12(11).

PMID: 37698127 PMC: 10563594. DOI: 10.1530/EC-23-0253.

Diet as a Source of Acrolein: Molecular Basis of Aldehyde Biological Activity in Diabetes and Digestive System Diseases.

Hikisz P, Jacenik D Int J Mol Sci. 2023; 24(7).

PMID: 37047550 PMC: 10095194. DOI: 10.3390/ijms24076579.

References

Luo J, Uchida K, Shi R . Accumulation of acrolein-protein adducts after traumatic spinal cord injury. Neurochem Res. 2005; 30(3):291-5. DOI: 10.1007/s11064-005-2602-7. View

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T . Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis. 2010; 211(2):475-9. DOI: 10.1016/j.atherosclerosis.2010.03.031. View

Yoshida M, Tomitori H, Machi Y, Katagiri D, Ueda S, Horiguchi K . Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis. 2008; 203(2):557-62. DOI: 10.1016/j.atherosclerosis.2008.07.022. View

Kehrer J, Biswal S . The molecular effects of acrolein. Toxicol Sci. 2000; 57(1):6-15. DOI: 10.1093/toxsci/57.1.6. View

Chen Z, Park J, Butler B, Acosta G, Vega-Alvarez S, Zheng L . Mitigation of sensory and motor deficits by acrolein scavenger phenelzine in a rat model of spinal cord contusive injury. J Neurochem. 2016; 138(2):328-38. PMC: 4936922. DOI: 10.1111/jnc.13639. View

Boor P, Sanduja R, Nelson T, Ansari G . In vivo metabolism of the cardiovascular toxin, allylamine. Biochem Pharmacol. 1987; 36(24):4347-53. DOI: 10.1016/0006-2952(87)90683-6. View

Goldman S, Kamel F, Ross G, Jewell S, Bhudhikanok G, Umbach D . Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012; 71(1):40-8. PMC: 3270814. DOI: 10.1002/ana.22499. View

Ambaw A, Zheng L, Tambe M, Strathearn K, Acosta G, Hubers S . Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. Mol Cell Neurosci. 2018; 88:70-82. DOI: 10.1016/j.mcn.2018.01.006. View

10.

Halagappa V, Guo Z, Pearson M, Matsuoka Y, Cutler R, LaFerla F . Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2007; 26(1):212-20. DOI: 10.1016/j.nbd.2006.12.019. View

11.

Zhu Q, Sun Z, Jiang Y, Chen F, Wang M . Acrolein scavengers: reactivity, mechanism and impact on health. Mol Nutr Food Res. 2011; 55(9):1375-90. DOI: 10.1002/mnfr.201100149. View

12.

Srivastava S, Sithu S, Vladykovskaya E, Haberzettl P, Hoetker D, Siddiqui M . Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis. 2011; 215(2):301-8. PMC: 3070047. DOI: 10.1016/j.atherosclerosis.2011.01.001. View

13.

Leuci R, Brunetti L, Poliseno V, Laghezza A, Loiodice F, Tortorella P . Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases. Foods. 2020; 10(1). PMC: 7824130. DOI: 10.3390/foods10010029. View

14.

Wang Y, Chang X, Zheng B, Chen Y, Xie J, Shan J . Protective Effect of Polysaccharide on Acrolein-Induced Apoptosis and Autophagic Flux in IEC-6 Cells. Foods. 2022; 11(2). PMC: 8774341. DOI: 10.3390/foods11020240. View

15.

Prasad M, Lovell M, Yatin M, Dhillon H, Markesbery W . Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 1998; 23(1):81-8. DOI: 10.1023/a:1022457605436. View

16.

Selley M . (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med. 1998; 25(2):169-74. DOI: 10.1016/s0891-5849(98)00021-5. View

17.

Yoshida M, Tomitori H, Machi Y, Hagihara M, Higashi K, Goda H . Acrolein toxicity: Comparison with reactive oxygen species. Biochem Biophys Res Commun. 2008; 378(2):313-8. DOI: 10.1016/j.bbrc.2008.11.054. View

18.

Zhao W, Wang H, Huang H, Lo Y, Lin A . Neuroprotective Effects of Baicalein on Acrolein-induced Neurotoxicity in the Nigrostriatal Dopaminergic System of Rat Brain. Mol Neurobiol. 2017; 55(1):130-137. DOI: 10.1007/s12035-017-0725-x. View

19.

Tayyarah R, Long G . Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Regul Toxicol Pharmacol. 2014; 70(3):704-10. DOI: 10.1016/j.yrtph.2014.10.010. View

20.

Speen A, Jones C, Patel R, Shah H, Nallasamy P, Brooke E . Mechanisms of CDDO-imidazolide-mediated cytoprotection against acrolein-induced neurocytotoxicity in SH-SY5Y cells and primary human astrocytes. Toxicol Lett. 2015; 238(1):32-42. DOI: 10.1016/j.toxlet.2015.07.005. View